March 28 (Reuters) - Palatin Technologies Inc PTN.A:
PALATIN ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 ULCERATIVE COLITIS (UC) STUDY OF ORAL MELANOCORTIN-1 RECEPTOR AGONIST PL8177
PALATIN: CLINICAL REMISSION ACHIEVED IN 33% OF PL8177-TREATED PATIENTS VERSUS 0% ON PLACEBO AFTER EIGHT WEEKS OF TREATMENT
PALATIN TECHNOLOGIES INC: SAFETY AND TOLERABILITY: EXCELLENT, WITH NO ADVERSE EVENTS
PALATIN: STATISTICALLY SIGNIFICANT CLINICAL RESPONSE SEEN IN 78% OF PL8177-TREATED PATIENTS VERSUS 33% ON PLACEBO AFTER 8 WEEKS OF TREATMENT
Source text: ID:nPn4BYDMga
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.